A mosquito-borne disease associated with birth defects. Since 1952, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, in 2015, in the Americas. According to the WHO, there is scientific consensus that Zika virus (ZIKV) is a cause of microcephaly and Guillain-Barré syndrome.

About VLA1601

  • VLA1601 is a highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine
  • Valneva reported positive Phase 1 results for its Zika vaccine candidate and seeks to partner the program


Additional information about Zika: